FOXC1 and cancer: While Bortezomib is required to be administered intravenously (IV), Ixazomib is an oral drug with a superior toxicity profile, making it an ideal candidate for evaluating therapeutic efficacy against FOXC1+ pro-metastatic cancers by targeting the NFĸB signaling pathway via proteasome inhibition.